Keke Palmer, PCOS, and Medication: What She Said and What It Means for You

What Keke Palmer Actually Said About PCOS and Medication

Keke Palmer addressed her PCOS diagnosis directly and on her own terms. In January 2023, she posted a TikTok video responding to comments that speculated about her appearance, stating plainly that she had been diagnosed with PCOS and that her symptoms, including hormonal acne and weight changes, were being managed with medication under a doctor's guidance. She later expanded on this in interviews, describing a period of frustration before diagnosis and expressing gratitude toward her medical team for finally identifying the root cause.

Palmer's account follows a pattern that many women with PCOS recognize: symptoms dismissed or misattributed, a delayed diagnosis, and visible physical changes that invite public scrutiny before a woman has had the chance to understand what is happening in her own body. She has not publicly named the specific medications she takes, which is her right. What she has confirmed is that medication is part of her current management plan.

The clinical takeaway here is not about Palmer's personal prescription. It is about why her story is medically significant for the estimated 8 to 13 percent of women of reproductive age who have PCOS, a condition that remains underdiagnosed and undertreated despite being the most common endocrine disorder in women.

Why Representation in PCOS Conversations Matters

PCOS presents differently depending on phenotype, ethnicity, and body composition. Research published in the Journal of Clinical Endocrinology and Metabolism has documented that Black women with PCOS are more likely to have hyperandrogenism and metabolic complications, yet they are also more likely to experience diagnostic delays. When a Black woman with a public platform names PCOS explicitly, it reaches communities that clinical messaging often does not.

Palmer described her acne as one of the most distressing symptoms, a response that aligns with data showing that up to 70 percent of women with PCOS experience hyperandrogenism, with acne, hirsutism, and hair thinning among the most common presentations.

What "On Medication" Likely Means Clinically

Because Palmer has confirmed medication use without naming specific drugs, any clinical discussion of what she may take must be labeled as inference. The standard medications used for PCOS symptoms in a woman of reproductive age who is not currently trying to conceive include: combined oral contraceptives for cycle regulation and androgen suppression, spironolactone for androgen-driven acne and hirsutism, and metformin for insulin resistance and metabolic parameters. Inositol supplements, specifically myo-inositol, are also widely used. Each of these is discussed in detail below.

What Is PCOS? The Physiology Every Woman Deserves to Understand

PCOS is not simply a reproductive condition. It is a complex endocrine disorder characterized by at least two of three diagnostic criteria under the Rotterdam consensus: oligo- or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound, in the absence of other causes. The 2023 International Evidence-Based Guideline for PCOS endorses the Rotterdam criteria as the current diagnostic standard.

The Hormonal Architecture

In PCOS, the hypothalamic-pituitary-ovarian axis is dysregulated. Elevated LH pulse frequency drives excess androgen production from the theca cells of the ovary. Simultaneously, insulin resistance, present in approximately 65 to 70 percent of women with PCOS, amplifies ovarian androgen output and suppresses SHBG production in the liver, leaving more free testosterone circulating in the blood. This is why symptoms like acne, hair loss on the scalp, and excess facial or body hair are so common: they are downstream effects of elevated free androgens.

PCOS Across the Life Span

Symptoms and treatment priorities shift considerably depending on life stage.

During the reproductive years, the focus is usually on cycle regulation, androgen-driven symptoms like acne and hirsutism, and metabolic health. For women who are trying to conceive, ovulation induction moves to the center of treatment. Postpartum, some women experience a flare in androgen-driven symptoms as contraception choices change. As women approach perimenopause, the hormonal picture becomes more complex: androgens may remain elevated while estrogen begins to fluctuate, and the long-term metabolic risks of PCOS, including a higher likelihood of type 2 diabetes and cardiovascular risk factors, become more clinically pressing. The 2023 International PCOS Guideline explicitly addresses the need for cardiovascular risk screening across the life span in women with PCOS.

Medications Used for PCOS: What the Evidence Says

Each of the major medication categories used in PCOS carries its own evidence base, its own hormonal considerations, and its own pregnancy and lactation profile. Understanding the difference matters.

Combined Oral Contraceptives

Combined oral contraceptives (COCs) are among the most widely prescribed treatments for PCOS symptom management in women who are not trying to conceive. They suppress LH, reduce ovarian androgen production, and increase hepatic SHBG production, all of which lower free testosterone. The result, for many women, is improved cycle regularity, reduced acne, and slower progression of hirsutism.

The 2023 International PCOS Guideline recommends COCs as a first-line pharmacological treatment for menstrual irregularity and hyperandrogenism in women with PCOS who do not want to conceive. Progestin type matters: formulations containing cyproterone acetate or drospirenone have anti-androgenic properties that may offer additional benefit for acne and hirsutism, though thromboembolism risk is modestly higher with drospirenone-containing pills compared to levonorgestrel formulations, and this risk is relevant to women with PCOS who may already have metabolic risk factors.

Pregnancy and lactation note: COCs are contraindicated during pregnancy. If a woman stops her pill to conceive, PCOS-related anovulation may return immediately, and ovulation induction may be needed. COCs are generally not recommended during breastfeeding in the first six weeks postpartum due to potential effects on milk supply; progestin-only options are preferred in the early postpartum period.

Spironolactone

Spironolactone is an aldosterone antagonist that also blocks androgen receptors and inhibits 5-alpha reductase activity. At doses of 50 to 200 mg per day, it is effective for reducing acne, hirsutism, and androgenic alopecia in women with PCOS. It does not reliably regulate cycles on its own, so it is usually combined with a COC in women who need cycle control as well.

Pregnancy and lactation note: Spironolactone is teratogenic. It has caused feminization of male fetuses in animal studies, and the FDA labels it as contraindicated in pregnancy. Any woman of reproductive potential taking spironolactone must use reliable contraception. This is not optional. If you are considering pregnancy, spironolactone should be discontinued before attempting to conceive, with a washout period discussed with your clinician. Data on transfer into breast milk are limited; most guidelines advise against use during lactation.

Metformin

Metformin is a biguanide insulin sensitizer that reduces hepatic glucose production and improves peripheral insulin sensitivity. In PCOS, it lowers circulating insulin, which in turn reduces ovarian androgen production and can restore ovulatory cycles in some women. The 2023 International PCOS Guideline recommends metformin for metabolic features of PCOS, and it may also modestly improve cycle regularity and reduce androgen levels, though it is generally less effective than COCs for these outcomes in isolation.

A typical starting dose is 500 mg once daily with food, titrated to 1500 to 2000 mg per day over several weeks to minimize gastrointestinal side effects. Extended-release formulations reduce nausea for many women.

Pregnancy and lactation note: Metformin has the most permissive pregnancy data of the commonly used PCOS medications. It is classified as FDA pregnancy category B (older classification) and is used during pregnancy in women with type 2 diabetes and gestational diabetes. In PCOS specifically, some clinicians continue metformin through the first trimester to reduce miscarriage risk, though the evidence for this is mixed and the decision should be individualized. Metformin does transfer into breast milk at low levels, and most major guidelines consider it compatible with breastfeeding.

Letrozole and Clomiphene: For Women Trying to Conceive

For women with PCOS who want to become pregnant, the treatment field shifts entirely. Ovulation induction rather than symptom suppression becomes the goal. Letrozole, an aromatase inhibitor, is now the first-line ovulation induction agent for anovulatory PCOS according to the ASRM and the 2023 International PCOS Guideline, having displaced clomiphene citrate in recent years. The PPCOSII trial published in the New England Journal of Medicine demonstrated a significantly higher live-birth rate with letrozole (27.5%) compared to clomiphene (19.1%) in women with PCOS. Letrozole is used only during specific days of the cycle; it is not a daily maintenance medication.

Pregnancy note: Neither letrozole nor clomiphene is used during confirmed pregnancy. Both are ovulation induction agents taken before ovulation to stimulate follicular development.

Inositol

Myo-inositol and D-chiro-inositol are naturally occurring compounds that act as insulin second messengers. They are not FDA-approved drugs but are widely used as supplements in PCOS management. A 2022 Cochrane review found some evidence that myo-inositol improves ovulation rates and hormonal parameters in PCOS compared to placebo, though the quality of evidence was rated as low to moderate. The typical dose studied is 4 g myo-inositol per day, often in a 40:1 ratio with D-chiro-inositol.

Inositol is generally considered safe in pregnancy, though high-quality human safety data are limited. Women who are pregnant or trying to conceive should discuss use with their provider before continuing supplementation.

PCOS, Skin, and Hair: The Androgen Connection

Palmer named acne as a central symptom. This is clinically consistent. Hyperandrogenism drives excess sebum production and follicular keratinization, and PCOS-related acne tends to concentrate along the jawline, chin, and neck, a distribution that reflects androgen receptor density in that region of the face.

A 2016 study in the Journal of the American Academy of Dermatology found that among women presenting to dermatologists with persistent adult acne, PCOS was identified in approximately 37 percent when systematically evaluated. Many of these women had not been previously diagnosed.

Androgenic alopecia in women with PCOS differs from male-pattern hair loss. It typically presents as diffuse thinning at the crown and widening of the central part rather than a receding hairline. Spironolactone is the most studied pharmacological option for this presentation in women, with evidence supporting its use at doses of 100 to 200 mg per day, though response can take six to twelve months.

Metabolic Health and the Long View

PCOS is associated with a three- to sevenfold increased risk of type 2 diabetes compared to age-matched women without the condition. It is also associated with higher rates of hypertension, dyslipidemia, and non-alcoholic fatty liver disease. These risks persist after menopause, when the ovulatory dysfunction that originally defined the diagnosis may resolve but the underlying metabolic phenotype does not.

This is why the 2023 International PCOS Guideline recommends screening all women with PCOS for impaired glucose tolerance using an oral glucose tolerance test, not just fasting glucose, at diagnosis and every one to three years thereafter depending on risk factors.

GLP-1 receptor agonists such as semaglutide are now being studied in PCOS, particularly in women with obesity and insulin resistance. Preliminary data are promising, but the 2023 PCOS Guideline does not yet endorse GLP-1 agonists as standard PCOS-specific treatment outside of their approved indications for type 2 diabetes and weight management. This is an area to watch.

Who This Treatment Approach Is Right For, and Who Should Pause

Understanding which medication fits which woman requires matching symptoms, life stage, and reproductive goals.

Combined oral contraceptives are appropriate if you have PCOS with irregular cycles and androgen-driven symptoms, are not trying to conceive, have no contraindications to estrogen (migraine with aura, personal history of VTE, certain cardiovascular risk factors), and want reliable contraception simultaneously.

Spironolactone is appropriate if acne, hirsutism, or androgenic hair loss is your primary concern, you are not pregnant and are using reliable contraception, and you can tolerate the need for regular potassium and blood pressure monitoring.

Metformin is appropriate if you have metabolic features of PCOS (elevated fasting glucose, insulin resistance, impaired glucose tolerance), want to improve ovulatory frequency, or are being managed through a trying-to-conceive pathway where ovulation induction is the next step.

Letrozole is appropriate if you have anovulatory PCOS and are actively trying to conceive, under the supervision of a reproductive endocrinologist or OB-GYN with experience in ovulation induction.

Inositol supplementation may be appropriate if you want a lower-intervention first step, have mild metabolic features, or are in a trying-to-conceive phase and your provider agrees it fits your profile.

Pause and discuss with your provider if you are perimenopausal, because the diagnostic criteria and treatment targets shift. Cycle irregularity in perimenopause has a different hormonal driver than PCOS-related anovulation, and the two can coexist. The long-term metabolic risks of PCOS do not disappear in perimenopause, but the hormonal management picture changes considerably.

The Evidence Gap: What We Do Not Know About PCOS in Women of Color

Women have historically been underrepresented in clinical trials, and within women's health research, Black women are particularly underrepresented. Most of the large PCOS medication trials have enrolled predominantly white, often European cohorts. The PPCOSII trial, for example, did include racially diverse participants, but subgroup analyses by race were not powered to detect differential treatment responses.

This matters because PCOS phenotype may differ by ethnicity. Research has suggested that Black women with PCOS have higher rates of metabolic complications even at lower body weights, and that hyperandrogenism may be more severe. Whether standard dosing and treatment targets are optimal across all ethnic groups has not been rigorously studied. When your clinician extrapolates data from majority-white trials to your care, that is exactly the kind of limitation worth naming explicitly in a clinical conversation.

Pregnancy, Lactation, and Contraception: Summary Table for PCOS Medications

| Medication | Safe in Pregnancy? | Safe While Breastfeeding? | Contraception Required? | |---|---|---|---| | Combined oral contraceptives | No. Contraindicated. | Avoid in first 6 weeks postpartum; progestin-only preferred | Not applicable (is contraception) | | Spironolactone | No. Teratogenic. Contraindicated. | Not recommended | Yes. Reliable contraception mandatory. | | Metformin | Generally yes, with monitoring | Generally compatible | No | | Letrozole (ovulation induction) | Not used during pregnancy | Not applicable | No (used to achieve pregnancy) | | Myo-inositol | Likely safe; data limited | Likely safe; data limited | No |

Women with PCOS who are on spironolactone and considering pregnancy should work with their provider to establish a transition plan: stopping spironolactone, confirming a washout period, and shifting to pregnancy-compatible management before attempting conception.

PCOS and Mental Health: A Connection That Deserves More Airtime

Palmer has spoken openly about the emotional toll of visible symptoms before diagnosis, and the clinical data back up that experience. Women with PCOS have significantly higher rates of depression and anxiety than the general female population. A 2018 meta-analysis in Human Reproduction found that women with PCOS had approximately three times the odds of depression and nearly three times the odds of anxiety compared to women without PCOS. Effective treatment of PCOS symptoms does not automatically resolve psychological distress; mental health support should be part of a complete care plan.